Scarica l'app Stockscreener
116.10
2.03%
-2.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$118.51
Aprire:
$119
Volume 24 ore:
794.94K
Relative Volume:
0.62
Capitalizzazione di mercato:
$12.55B
Reddito:
$769.10M
Utile/perdita netta:
$46.67M
Rapporto P/E:
331.71
EPS:
0.35
Flusso di cassa netto:
$119.79M
1 W Prestazione:
+5.27%
1M Prestazione:
-6.05%
6M Prestazione:
+186.88%
1 anno Prestazione:
+40.34%
Intervallo 1D:
$114.51
$120.44
Intervallo di 1 settimana:
$109.00
$120.44
Portata 52W:
$28.66
$126.38
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
116.10 | 12.55B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2026-03-26 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Iniziato | UBS | Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT) - Yahoo Finance
Corcept Therapeutics Announces New Endocrinology Division President - The Globe and Mail
The Escalator: Bavarian Nordic, Acumetis, Corcept and more - Medical Marketing and Media
About Corcept Therapeutics Incorporated rStock - Coinbase
CORT Looks 59.9% Overvalued on GF Value™ - GuruFocus
Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires - citybiz
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant - TradingView
Corcept names Justin Gunn to lead endocrinology division By Investing.com - Investing.com Canada
Corcept Announces Planned Leadership Transition - Business Wire
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - stocktwits.com
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus - Yahoo Finance
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle - Yahoo Finance
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Your Wyoming Link
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to S&P 400 Health Care - marketscreener.com
Corcept Therapeutics shares surge 22% after Q2 beat, guidance raise - scanx.trade
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE) - The Globe and Mail
Corcept Therapeutics president Vieira sells $29,842 of stock By Investing.com - Investing.com South Africa
Corcept Therapeutics president Vieira sells $29,842 of stock - Investing.com
Corcept Therapeutics (CORT) oncology president sells shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History - Benzinga
Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years - webull.com
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week - Seeking Alpha
Corcept Therapeutics Incorporated Receives CHMP Recommendation For EU Marketing Authorization For Lifyorli (Relacorilant) Combined With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer - marketscreener.com
CORT Looks 57.2% Overvalued on GF Value™ Amid EMA Relacorilant N - GuruFocus
Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval - marketscreener.com
Corcept’s relacorilant receives EU panel backing for ovarian cancer By Investing.com - Investing.com Canada
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant) - STT Info
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup - ChartMill
Corcept (CORT) director offloads 10,000 shares under preset plan - Stock Titan
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? - Eastern Progress
Corcept Grows to Mid-Cap on Institutional Support - FXEmpire
Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks - Moomoo
Corcept Therapeutics (CORT) director plans $3.34M stock sale - Stock Titan
Stock option exercise to drive 10,000-share sale at Corcept (NASDAQ: CORT) - Stock Titan
Corcept Therapeutics (CORT) Short Interest & Short Float | Updated Sep 2026 $CORT - MarketBeat
Corcept Therapeutics posts strong Q2 revenue, e... - Pluang
Corcept president Sean Maduck sells $2.86m in stock By Investing.com - Investing.com South Africa
Corcept Therapeutics Insider Sold Shares Worth $2,860,737, According to a Recent SEC Filing - marketscreener.com
Corcept Therapeutics Insider Sold Shares Worth $6,460,766, According to a Recent SEC Filing - marketscreener.com
Corcept Therapeutics oncology president sells $6.46m in shares By Investing.com - Investing.com UK
Corcept president Sean Maduck sells $2.86m in stock - Investing.com
Corcept Therapeutics oncology president sells $6.46m in shares - investing.com
Corcept Therapeutics (CORT) CFO adds shares via plan and restricted awards - Stock Titan
Corcept (CORT) oncology president reports shares and 480K options - stocktitan.net
CORCEPT Therapeutics Officer Vieira Roberto Wandenkolk to Sell 75,295 Shares Including 74,999 Stock Options (NASDAQ: CORT) - Kalkine Media
$8.3M stock sale planned at Corcept (NASDAQ: CORT) - Stock Titan
QQQ Stock Price TodayGet QQQ News, Analysis and Trading Ideas - Stocktwits
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report? - Yahoo Finance
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - Kalkine Media
Corcept (NASDAQ: CORT) director to sell 26,685 shares - Stock Titan
$22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT) - Stock Titan
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corcept Therapeutics Inc Azioni (CORT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Robb Gary Charles | Chief Business Officer |
Sep 17 '26 |
Option Exercise |
8.27 |
17,493 |
144,667 |
31,156 |
| Lyon Joseph Douglas | See Remarks |
Sep 14 '26 |
Option Exercise |
12.99 |
10,000 |
129,863 |
15,683 |
| Lyon Joseph Douglas | See Remarks |
Sep 14 '26 |
Sale |
113.49 |
10,000 |
1,134,947 |
5,683 |
| WILSON JAMES N | Director |
Sep 15 '26 |
Sale |
110.69 |
10,000 |
1,106,940 |
1,064,543 |
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):